Kelonia Therapeutics
Michael McDonald serves as Senior Vice President, Head of IP and Legal Affairs, and Corporate Secretary at Kelonia Therapeutics since September 2022. Previously, Michael held the position of Vice President, Head of RNA Writing IP at Tessera Therapeutics for a brief period in August 2022, and during a significant tenure at bluebird bio from November 2015 to July 2022 as Vice President, Chief IP Counsel, and in various senior roles including Senior Director and Director of Intellectual Property. Prior legal experience includes serving as a Patent Attorney at Cooley LLP and a Patent Agent at Seed IP Law Group. Michael's educational background includes a Doctor of Law (J.D.) from Seattle University, a Doctor of Philosophy (Ph.D.) and Master's of Science in Cell/Cellular and Molecular Biology from Brandeis University, a Bachelor of Science in Biological Sciences from Colorado State University, and initial education at Colorado College and Durango High School.
This person is not in any teams
This person is not in any offices
Kelonia Therapeutics
1 followers
Kelona is revolutionizing gene delivery to expand the impact of genetic medicines. Their goal is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.